Abstracts by keywords: Utility Assessment
“Patient-relevant endpoints” – assessment from the patient’s perspective?
Most decision makers, including IQWiG, consider various patient-relevant endpoints to demonstrate the superiority of a therapy over a placebo or a comparator. The question arises: How can contradictory results in different endpoints be interpreted? The problem in benefit assessments with more than one endpoint is the weighting and the subsequent calculation of a key figure for the overall benefit. Without the aggregation of several endpoints into a score/index, the derivation of recommendations or regulatory decisions could be questionable.